News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
481,187 Results
Type
Article (36367)
Company Profile (71)
Press Release (444749)
Multimedia
Podcasts (50)
Webinars (8)
Section
Business (146653)
Career Advice (1596)
Deals (27490)
Drug Delivery (99)
Drug Development (65193)
Employer Resources (132)
FDA (11498)
Job Trends (10535)
News (255868)
Policy (27780)
Tag
Academia (2103)
Accelerated approval (4)
Adcomms (25)
Allergies (77)
Alliances (44812)
ALS (72)
Alzheimer's disease (1211)
Antibody-drug conjugate (ADC) (122)
Approvals (11479)
Artificial intelligence (203)
Autoimmune disease (17)
Automation (11)
Bankruptcy (253)
Best Places to Work (8738)
BIOSECURE Act (16)
Biosimilars (90)
Biotechnology (48)
Bladder cancer (61)
Brain cancer (29)
Breast cancer (218)
Cancer (1876)
Cardiovascular disease (150)
Career advice (1334)
Career pathing (24)
CAR-T (122)
Cell therapy (347)
Cervical cancer (18)
Clinical research (52787)
Collaboration (757)
Company closure (1)
Compensation (481)
Complete response letters (21)
COVID-19 (2559)
CRISPR (37)
C-suite (186)
Cystic fibrosis (61)
Data (1841)
Decentralized trials (1)
Denatured (11)
Depression (41)
Diabetes (246)
Diagnostics (4393)
Digital health (13)
Diversity (4)
Diversity, equity & inclusion (38)
Drug discovery (100)
Drug pricing (107)
Drug shortages (28)
Duchenne muscular dystrophy (89)
Earnings (60078)
Editorial (42)
Employer branding (20)
Employer resources (117)
Events (60978)
Executive appointments (473)
FDA (12559)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (7)
Funding (563)
Gene editing (85)
Generative AI (17)
Gene therapy (270)
GLP-1 (735)
Government (4276)
Grass and pollen (5)
Guidances (141)
Healthcare (13507)
Huntington's disease (20)
IgA nephropathy (29)
Immunology and inflammation (102)
Indications (26)
Infectious disease (2707)
Inflammatory bowel disease (98)
Inflation Reduction Act (7)
Influenza (55)
Intellectual property (80)
Interviews (279)
IPO (12400)
IRA (41)
Job creations (2173)
Job search strategy (1159)
Kidney cancer (7)
Labor market (25)
Layoffs (344)
Leadership (12)
Legal (7369)
Liver cancer (63)
Lung cancer (270)
Lymphoma (120)
Machine learning (8)
Management (41)
Manufacturing (274)
MASH (64)
Medical device (8106)
Medtech (8107)
Mergers & acquisitions (15543)
Metabolic disorders (657)
Multiple sclerosis (60)
NASH (20)
Neurodegenerative disease (84)
Neuropsychiatric disorders (26)
Neuroscience (1671)
NextGen: Class of 2025 (4422)
Non-profit (3304)
Now hiring (9)
Obesity (365)
Opinion (217)
Ovarian cancer (61)
Pain (61)
Pancreatic cancer (74)
Parkinson's disease (135)
Partnered (14)
Patents (187)
Patient recruitment (76)
Peanut (42)
People (35862)
Pharmaceutical (24)
Pharmacy benefit managers (11)
Phase I (15948)
Phase II (22986)
Phase III (18388)
Pipeline (1172)
Policy (146)
Postmarket research (2079)
Preclinical (6758)
Press Release (35)
Prostate cancer (89)
Psychedelics (28)
Radiopharmaceuticals (230)
Rare diseases (290)
Real estate (3415)
Recruiting (54)
Regulatory (18101)
Reports (26)
Research institute (1857)
Resumes & cover letters (244)
Rett syndrome (5)
RNA editing (3)
RSV (47)
Schizophrenia (71)
Series A (94)
Series B (58)
Service/supplier (5)
Sickle cell disease (40)
Special edition (9)
Spinal muscular atrophy (146)
Sponsored (21)
Startups (2320)
State (1)
Stomach cancer (12)
Supply chain (60)
Tariffs (48)
The Weekly (38)
Vaccines (743)
Venture capitalists (34)
Weight loss (262)
Women's health (16)
Worklife (13)
Date
Today (133)
Last 7 days (728)
Last 30 days (2373)
Last 365 days (23757)
2025 (8764)
2024 (25737)
2023 (29241)
2022 (38627)
2021 (41777)
2020 (39994)
2019 (33592)
2018 (25643)
2017 (24574)
2016 (22868)
2015 (26590)
2014 (19816)
2013 (16096)
2012 (17199)
2011 (18020)
2010 (16332)
Location
Africa (682)
Alabama (32)
Alaska (3)
Arizona (109)
Arkansas (5)
Asia (31463)
Australia (5553)
California (4384)
Canada (1516)
China (453)
Colorado (184)
Connecticut (180)
Delaware (123)
Europe (73632)
Florida (681)
Georgia (145)
Hawaii (1)
Idaho (38)
Illinois (356)
India (24)
Indiana (236)
Iowa (8)
Japan (151)
Kansas (78)
Kentucky (16)
Louisiana (11)
Maine (52)
Maryland (731)
Massachusetts (3157)
Michigan (137)
Minnesota (205)
Mississippi (1)
Missouri (58)
Montana (23)
Nebraska (16)
Nevada (46)
New Hampshire (40)
New Jersey (1375)
New Mexico (19)
New York (1285)
North Carolina (680)
North Dakota (5)
Northern California (1960)
Ohio (141)
Oklahoma (7)
Oregon (13)
Pennsylvania (979)
Puerto Rico (7)
Rhode Island (13)
South America (978)
South Carolina (18)
South Dakota (1)
Southern California (1687)
Tennessee (66)
Texas (575)
United States (16403)
Utah (117)
Virginia (105)
Washington D.C. (44)
Washington State (367)
West Virginia (2)
Wisconsin (40)
481,187 Results for "novartis international ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
March 19, 2025
·
6 min read
·
Heather McKenzie
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
·
2 min read
·
Dan Samorodnitsky
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Deals
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
MorphoSys AG announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024.
June 20, 2024
·
10 min read
Earnings
Novartis CEO Brushes Off Tariffs but Says Trump Pricing Controls Would Be ‘Devastating’
Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at their medium- to long-term outlook.”
April 29, 2025
·
3 min read
·
Annalee Armstrong
Manufacturing
Novartis Pledges $23B Boost to US Ops as Trump Intensifies Tariff Threats
Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The new facilities will include a biomedical research hub in California, two radioligand plants, and four manufacturing sites.
April 11, 2025
·
2 min read
·
Tristan Manalac
Opinion
Bringing Neurological Disease Into the Age of Precision Medicine
To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of protein aggregates in the brain.
May 12, 2025
·
5 min read
·
John McDonough
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
February 11, 2025
·
2 min read
·
Tristan Manalac
1 of 48,119
Next
